RxSight (RXST)
Sells adjustable cataract lenses, light-delivery devices, and related service for ophthalmology practices.
Something off on this page? Send us feedback.
Commercializes the RxSight Light Adjustable Lens system for cataract surgery, combining LAL/LAL+ lenses with the Light Delivery Device and accessories. Revenue is driven mainly by recurring lens use after practices adopt the LDD, with commercial efforts centered on cataract surgeons in the United States and newer international launches.
Commercializes the RxSight Light Adjustable Lens system, a premium cataract technology built around LAL/LAL+ intraocular lenses, the Light Delivery Device, and related accessories and service. The lens is adjusted after implantation using programmed ultraviolet light delivered by the LDD.
Sales are concentrated on cataract practices in the United States, supported by direct device sales, account managers, clinical specialists, field service engineers, and marketing staff. Recent expansion has added launches or regulatory approvals in selected Asia-Pacific markets.
The model depends on LDD adoption translating into recurring LAL procedure volume. Larger premium intraocular-lens companies remain competitors, while Alcon is also a non-exclusive future-product partner. RxSight handles development and manufacturing and receives royalties, and Alcon leads global commercialization. FDA approvals, surgeon workflow adoption, installed-base productivity, and collaboration execution shape the pace of growth.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Jefferies | Target | Target: $6.50 | Target: $5.75 |
| Aug 10, 2026 | Stifel Nicolaus | Target | Target: $9 | Target: $7 |
| Jul 28, 2026 | UBS | Target | Target: — | Target: $5.50 |
| Jul 7, 2026 | Jefferies | Target | Target: $72 | Target: $6.50 |
| May 7, 2026 | Needham | Reiterate | Rating: —Target: $13 | Target: $11 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $208.8M · Total debt $10.6M · Total assets $352.7M · Shareholders' equity $263.3M
- Revenue
- $33.7M
- Operating income
- −$13.8M
- Net income
- −$12.1M
No dividends on record.
| Institutions | ≈ 100.68% | 41.88M shares | |
|---|---|---|---|
| 154 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.68% | 1.95M shares | |
| 15 holders · as of Sep 16, 2026 | |||
| Strategic holders | 12.12% | 5.04M shares | |
| 2 holders · as of Jul 17, 2026 | |||
| Adds to | 117.48% | ||
41.59M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 117.48%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 13.92% | 5.79M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 7.29% | 3.03M | as of Jun 30, 2026 |
BlackRock Portfolio Management LLCStrategic | 7.17% | 2.98M | filed Jul 17, 2026 |
Artisan Partners Asset Management Inc.Strategic | 4.95% | 2.06M | filed May 13, 2026 |
No Street GP LPInstitution | 4.94% | 2.06M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Eric Weinberg | officer: See remarks | −2,041 | $6.96 |
| Sep 2, 2026 | Ilya Goldshleger | officer: Chief Operating Officer | −2,041 | $6.96 |
| Sep 2, 2026 | Mark Wilterding | officer: Chief Financial Officer | −7,765 | $6.96 |
| Sep 2, 2026 | Ronald M. MD Kurtz | officer: Chief Medical Officer | −5,100 | $6.96 |
- Alcon
Largest premium-IOL rival and future adjustable-PCIOL partner
- Johnson & Johnson
TECNIS premium IOLs and surgical vision challenge LAL adoption
- Bausch + Lomb
enVista premium IOLs and cataract systems compete for surgeons
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| RxSight | $4.93 | 0.00% | $212.8M | — | — | 1.7 | +0.3% |
| Alcon | $65.59 | 0.00% | $31.64B | 49.9 | 17.3 | 2.9 | +7.5% |
| Johnson & Johnson | $269.61 | +0.12% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Bausch + Lomb | $17.32 | −0.06% | $6.00B | — | 17.4 | 1.1 | +9.1% |
| Median | 40.6 | 17.4 | 2.9 | +7.5% |